Dear Editor, In their July issue paper, Hodgkins et al. concluded that "European patients may benefit from better standardization of ADHD management across countries and additional treatment options" [2] .
Another important bias of the study is the long follow-up period (2-5 years), knowing that ADHD symptoms are affected by the duration and type of treatment [3] .
Since only 34.5 % of included patients were treated with a combination of pharmacotherapy and BT, according to NICE guideline recommendations [4] , only 30.8 % of patients would be expected to show "complete symptom control."
Lastly, the profile of ADHD management resulting from this study is completely different from the Italian reality [1, 5] .
One of the acknowledged needs of ADHD patients is effective evidence-based interventions, and this can be achieved through (useful) data collection, assessment of prevalence, case identification, and outcome measurements. This work does not seem to contribute to this aim.
